The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Open accessAbstract
Background: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger. Objective: This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research. Methods: Taking a high-level perspective, we address both psychological and psychiatric risks, such as abuse liability and potential for dependence, as well as medical harms, including toxicity and overdose. We explore the evidence base for these adverse effects to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny. Results: Our review shows that medical risks are often minimal, and that many – albeit not all – of the persistent negative perceptions of psychological risks are unsupported by the currently available scientific evidence, with the majority of reported adverse effects not being observed in a regulated and/or medical context. Conclusions: This highlights the importance for clinicians and therapists to keep to the highest safety and ethical standards. It is imperative not to be overzealous and to ensure balanced media reporting to avoid future controversies, so that much needed research can continue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Bulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 4×
“…treatment (combined with psychotherapy) for obsessive compulsive disorder (OCD) (Moreno et al., 2006), treatment-resistant depression (TRD) (Carhart-Harris et al., 2016), smoking cessation (Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015), leading to an increasing body of…”
BackgroundInfluentialSelf-citationTrial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Self-citationAnthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Cited by
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
“A recent non-systematic, narrative review explored the evidence base for the most frequently mentioned AEs in public discourse, to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny (Schlag et al., 2022).”
BackgroundPsychiatric risks for worsened mental health after psychedelic use
Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241232548 · Cited by 60
Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Self-citationPepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Calder, A. E., & Hasler, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.091 · Cited by 28
Metadata
- Authors
- Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-02-02
- Volume
- 36
- Issue
- 3
- Pages
- 258-272
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W4210376981
- Cited by
- 325
- References
- 131
- FWCI
- 60.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. https://app.cochat.ai/papers/10.1177/02698811211069100
- The paper
- Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211069100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.